Cerebral cysticercosis in a European patient: problems of disease activity and therapeutic implications.
The case of a German patient who was treated with two courses of praziquantel for parenchymal cerebral cysticerosis (CC) is reported. Efficacy of the treatment could not reliably be distinguished from the natural course of the disease. After a brief review of the literature concerning problems with assessment of the activity of CC, the criteria recommending praziquantel therapy are discussed.
D000328:Adult; D001927:Brain Diseases / Q000175:diagnosis / Q000188:drug therapy*; D003551:Cysticercosis / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000627:therapeutic use; D011223:Praziquantel / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D010672:Phenytoin; D011223:Praziquantel